Mesa Laboratories, Inc. — Form 10-Q Summary
Reporting period: Three months ended June 30, 2015. The request metadata identifies “2014 Q1,” but the filing itself clearly reports the quarter ended June 30, 2015, with comparison to June 30, 2014. The filing was dated August 4, 2015.
Business Context
Mesa develops and sells quality-control products and services in niche, regulation-driven markets. Its reporting segments are Biological Indicators, Instruments, and Continuous Monitoring. The company also describes a Cold Chain division, including monitoring, consulting, packaging, and validation services.
Key Financial Metrics
| Metric | Q1 FY2016 | Q1 FY2015 | Change |
|---|---|---|---|
| Revenue | $18.158 million | $16.400 million | Up 11% |
| Gross profit | $11.141 million | $9.705 million | Up 15% |
| Gross margin | 61% | 59% | Up 2 percentage points |
| Operating income | $3.642 million | $3.055 million | Up 19% |
| Net income | $2.306 million | $1.881 million | Up 23% |
| Net margin | 13% | 11% | Up 2 percentage points |
| Diluted EPS | $0.63 | $0.51 | Up 24% |
| Operating cash flow | $2.861 million | $0.426 million | Up $2.435 million |
Revenue by segment was $7.236 million for Biological Indicators, $8.331 million for Instruments, and $2.591 million for Continuous Monitoring. Segment revenue increased 13%, 8%, and 13%, respectively.
Cash and equivalents were $1.968 million at June 30, 2015, compared with $2.034 million at March 31, 2015. Working capital was $16.277 million, compared with $14.965 million at March 31, 2015. Total assets were $117.189 million.
Total debt was $35.000 million at June 30, 2015, consisting of a $13.000 million line-of-credit balance and a $12.000 million term loan, with $3.000 million classified as current. The company was in compliance with its debt covenants at quarter-end.
Material Changes Versus the Prior Comparable Period
- Revenue growth reflected acquisitions and organic growth. Biological Indicators benefited from the ATI, PCD, Früh, and Cherwell acquisitions, although organic growth was flat.
- Instruments revenue increased due to the timing of the BGI acquisition and 7% organic growth in existing product lines.
- Continuous Monitoring revenue increased 13% organically.
- Biological Indicators gross margin rose to 66% from 59%, reflecting acquisitions, price increases, and volume efficiencies.
- Instruments gross margin remained approximately 64%. Continuous Monitoring gross margin declined to 40% from 43%, primarily due to product and service mix.
- Selling expense decreased 13%, primarily because of lower bad-debt and personnel costs.
- General and administrative expense increased 23%, driven by acquisition-related amortization and personnel costs, as well as the ERP system upgrade.
- Research and development expense increased 28% because of additional product and software engineering personnel.
- Operating cash flow improved substantially, aided by working-capital management and a $966,000 reduction in accounts receivable, but included a $1.120 million payment or reduction related to contingent consideration.
- Investing cash use declined to $1.675 million from $14.210 million because the prior-year period included the $10.268 million BGI acquisition.
Guidance, Outlook, Risks, and Unusual Items
- Management expects an effective tax rate of approximately 35% to 37% for the year ending March 31, 2016.
- Management believes cash from operations, available credit, and other financing sources will satisfy short- and long-term needs.
- In July 2015, Mesa acquired Infitrak for approximately $9.6 million, with up to approximately $12 million of additional contingent consideration based on performance. The acquisition was funded through amended debt facilities.
- On July 1, 2015, the credit facility was extended to June 30, 2020. The revolving line increased to $50 million, and a new $20 million term loan was established. As of July 31, 2015, outstanding indebtedness was $33.25 million and unused credit capacity was $36 million.
- Mesa began construction of a new Bozeman, Montana facility in July 2015. The remaining expected cost was approximately $14 million, with completion targeted no later than September 30, 2016. The existing facility may be sold for approximately $2 million to $3 million.
- The ERP system was expected to go live in the quarter ending December 31, 2015. Additional implementation and post-go-live costs were estimated at $500,000 to $750,000.
- Contingent consideration liabilities included $500,000 related to the Amega earn-out and $300,000 related to the PCD agreement. Changes in estimates could affect future income or expense.
- Amega and its former owner filed litigation seeking, among other amounts, up to $10 million under the earn-out, more than $500,000 in additional damages, accelerated stock options, and recovery of approximately $704,000 in withheld consideration. Mesa stated that the outcome and potential loss could not be estimated.
- Mesa had approximately $10.7 million of open purchase orders for routine supplies and inventory, payable within one year.
- Management stated that there were no material changes to the risk factors in the prior Form 10-K. The company reported minimal foreign-currency and commodity-market exposure and no derivative instruments.
- The board declared a quarterly dividend of $0.16 per share payable September 15, 2015.
Investor Verification Points
- Verify the period being analyzed: the filing is for June 30, 2015, not 2014 Q1.
- Review the July 2015 Infitrak acquisition, including purchase accounting, debt funding, and potential contingent consideration.
- Assess leverage, covenant compliance, interest-rate exposure, and the scheduled $750,000 quarterly term-loan repayments.
- Monitor the Amega litigation and the potentially material earn-out obligation.
- Evaluate whether Continuous Monitoring margin pressure improves through the stated cost-reduction initiatives.
- Track the Bozeman facility project, expected capital spending, and potential proceeds from sale of the existing facility.
- Assess execution risk and remaining costs associated with the ERP implementation.
- Confirm the effective tax rate and the impact of acquisition-related amortization and other non-cash expenses on reported earnings.